11/8/26 Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways Previous Learning More from Less: Smarter Design and Execution in Rare Disease Trials Next Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients You Might Also Like Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support Mapping the Rare Patient Journey Accelerated Pathways and Global Harmonization The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales
11/8/26 Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways Previous Learning More from Less: Smarter Design and Execution in Rare Disease Trials Next Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients You Might Also Like Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support Mapping the Rare Patient Journey Accelerated Pathways and Global Harmonization The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales
